- UNH Price: Closed Friday (Nov 1) at $341.56 (down 0.93% on day), with market cap ~$309 billion. 52-week range ~$234.65–630.45.
- Q3 Results: Oct 28 report – revenues $113.2 B (+12% YoY) and EPS $2.59 (GAAP; $2.92 adjusted), both ahead of estimates. 2025 guidance raised to Adj. ≥$16.25 EPS.
- Analyst Sentiment: Wall Street’s median 12‑month target ≈$390quiverquant.com. 16 of 30 analysts rated UNH a “Buy”/“Overweight” (vs. 2 “Sell”)quiverquant.com. Recent price-target hikes include Bernstein $433 and KeyBanc $400quiverquant.comts2.tech. Consensus sees 2026 EPS ≈$17.60reuters.com.
- Stock Trends: After plunging ~30–35% YTD, UNH has rebounded ~10% off summer lows. The late-May low ~$245 vs. April high ~$630, meaning the stock still trades far below its 52-week peak. Insider/investor confidence: CEO Stephen Hemsley has bought shares, and Warren Buffett’s Berkshire added ~5 M UNH shares in Aug.
- Headwinds: UNH cut full‑year 2025 EPS guide drastically in April due to surging Medicare Advantage costs. It’s exiting ~100 Medicare Advantage plans (impact ~600k members) to stem losses. Regulatory/legal concerns linger (e.g. a federal fraud probe). Broader sector shocks – e.g. US Obamacare premiums set to more than double in 2026 – add uncertainty.
UnitedHealth’s volatile 2025 has made UNH a headline story heading into Nov. 3 trading. After a surprise earnings miss in Q1 and a CEO shakeup this spring, UNH plunged to four-year lows. In late Oct. the turnaround narrative got a boost: Q3 beat estimates and management raised guidancegurufocus.comgurufocus.com. CEO Stephen Hemsley (back at the helm) told investors he’s confident “we will return to solid earnings growth next year” thanks to “operational rigor and more prudent pricing”reuters.com. Guggenheim and Reuters note Hemsley’s comeback has reassured investors and even prompted Buffett to buy inreuters.comreuters.com.
Market analysts are increasingly upbeat. As of Nov. 1, UNH closed near $341.6reuters.com. Notably, TechStock²’s Oct. 21 analysis points out UNH “remains deep in the red for 2025” (–30–35% YTD) but has recovered about +10% off its summer troughts2.tech. Wall Street is divided: some remain cautious on cost pressures, but many have upped price targets this fallts2.techquiverquant.com. For example, Bernstein boosted its target to $433, KeyBanc to $400, and Goldman Sachs, Morgan Stanley, Barclays and others have moved targets well above the $300sts2.techquiverquant.com. QuiverQuant reports 22 analysts’ 12-month targets have a median of ~$390quiverquant.com. MarketBeat concurs that consensus upside is around +16%marketbeat.com.
UnitedHealth’s fundamentals remain strong but strained by costs. Q3 revenue of $113.2 B (up 12% YoY) surpassed Street estimatesgurufocus.com, driven by 16% growth in its UHC insurance arm and 8% in OptumRxgurufocus.com. However, margins suffered: adjusted EPS $2.92 missed last year’s pace, reflecting an 89.9% medical care ratio in line with expectationsgurufocus.com. Reuters observes that UNH’s leadership, including CFO Wayne DeVeydt, is trimming unprofitable businesses (like broad clinical services) to restore marginsreuters.com. Oppenheimer analyst Michael Wiederhorn says the cost-surge trends “are on track” (i.e. stabilizing) after management’s cleanup effortreuters.com. Overall, UNH raised full-year adjusted EPS guide to ≥$16.25gurufocus.com, above Street’s ~$16.20 prior consensusreuters.com – a sign that management thinks the worst of 2025’s cost shock is past.
Still, risks loom. Medical cost inflation and policy changes are top concerns. UnitedHealth cut 2025 EPS guidance earlier in 2025 because Medicare Advantage members used more care than expectedts2.tech. In Oct. it announced exiting about 100 Advantage plans (109 counties) to halt lossests2.techreuters.com. At the same time, regulators have been scrutinizing insurers; a Justice Dept. report earlier reported significant Medicare “star rating” cuts which UNH has since challenged in court. Broader healthcare trends add volatility: a Reuters Nov. 1 story warns ACA premiums will more than double next year without subsidiesreuters.com, likely slowing enrollment. On the positive side, peers like CVS are forecasting mid-teens profit growth in 2026reuters.com, indicating industry-wide improvement ahead.
Outlook: With markets closed Sunday, Monday’s open may see UNH react to global cues or sector news. TechStock² notes sentiment has turned cautiously optimistic, given recent buy-side support (Buffett, Ark, others) and the stock’s bounce off multi-year lowsts2.techreuters.com. Analysts caution earnings season jitters – next catalyst is likely Q4 guidance in Jan. – but the raised guidance and management confidence have revived the bull case. As Cerity Partners strategist Jim Lebenthal put it (via Reuters), “Hemsley is highly respected,” but he warned that systemic medical overuse could still pressure insurers long-termreuters.com.
Investors should monitor premarket indicators Monday and any overnight healthcare news. Key metrics to watch: UNH’s relative performance vs. the S&P/health indices, any Fed comments on inflation (which could affect discount rates), and updates on Medicare policy or related earnings from other insurers. Overall, UNH stock currently trades at a modest P/E ~18, with a 2.6% dividend yield. The balance between resumed growth (per Hemsley’s plan) and lingering sector risks will drive trading. In summary, UnitedHealth’s turnaround narrative – bolstered by strong Q3 results and analyst optimism – is in focus Monday. However, investors remain wary of the healthcare cost cycle and regulatory backdrop, making UNH a high-visibility story in tomorrow’s premarket session.
Sources: Latest earnings releases and SEC filings; Reuters & BusinessWire news; Market data (Reuters); analyst reports and commentary; industry news.
